Fate Therapeutics Statistics
Total Valuation
FATE has a market cap or net worth of $170.72 million. The enterprise value is $44.91 million.
Important Dates
The last earnings date was Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FATE has 115.35 million shares outstanding. The number of shares has increased by 4.49% in one year.
| Current Share Class | 115.35M |
| Shares Outstanding | 115.35M |
| Shares Change (YoY) | +4.49% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 63.05% |
| Float | 100.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.69 |
| Forward PS | 46.70 |
| PB Ratio | 0.82 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.79, with a Debt / Equity ratio of 0.38.
| Current Ratio | 5.79 |
| Quick Ratio | 5.67 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -51.84% and return on invested capital (ROIC) is -26.80%.
| Return on Equity (ROE) | -51.84% |
| Return on Assets (ROA) | -24.31% |
| Return on Invested Capital (ROIC) | -26.80% |
| Return on Capital Employed (ROCE) | -52.22% |
| Weighted Average Cost of Capital (WACC) | 11.43% |
| Revenue Per Employee | $36,718 |
| Profits Per Employee | -$753,122 |
| Employee Count | 181 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.59% in the last 52 weeks. The beta is 2.25, so FATE's price volatility has been higher than the market average.
| Beta (5Y) | 2.25 |
| 52-Week Price Change | +27.59% |
| 50-Day Moving Average | 1.17 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 60.46 |
| Average Volume (20 Days) | 1,748,835 |
Short Selling Information
The latest short interest is 11.13 million, so 9.65% of the outstanding shares have been sold short.
| Short Interest | 11.13M |
| Short Previous Month | 11.41M |
| Short % of Shares Out | 9.65% |
| Short % of Float | 11.05% |
| Short Ratio (days to cover) | 6.58 |
Income Statement
In the last 12 months, FATE had revenue of $6.65 million and -$136.32 million in losses. Loss per share was -$1.15.
| Revenue | 6.65M |
| Gross Profit | 6.65M |
| Operating Income | -147.70M |
| Pretax Income | -136.32M |
| Net Income | -136.32M |
| EBITDA | -134.80M |
| EBIT | -147.70M |
| Loss Per Share | -$1.15 |
Full Income StatementBalance Sheet
The company has $203.66 million in cash and $77.85 million in debt, with a net cash position of $125.81 million or $1.09 per share.
| Cash & Cash Equivalents | 203.66M |
| Total Debt | 77.85M |
| Net Cash | 125.81M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 207.18M |
| Book Value Per Share | 1.80 |
| Working Capital | 172.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$106.08 million and capital expenditures -$5.95 million, giving a free cash flow of -$112.04 million.
| Operating Cash Flow | -106.08M |
| Capital Expenditures | -5.95M |
| Free Cash Flow | -112.04M |
| FCF Per Share | -$0.97 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -2,222.45% |
| Pretax Margin | -2,051.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FATE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.49% |
| Shareholder Yield | -4.49% |
| Earnings Yield | -79.85% |
| FCF Yield | -65.63% |
Analyst Forecast
The average price target for FATE is $3.92, which is 164.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.92 |
| Price Target Difference | 164.87% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 94.80% |
| EPS Growth Forecast (5Y) | -12.75% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
